Development and Implementation of Proteomics Analysis into the Inova Molecular Tumor Board

This is a feasibility study to develop and implement the procedures and infrastructure necessary for proteomics analysis within the context of the Inova Schar Molecular Tumor Board. This study is being done to determine if proteomics testing can be done on cancer patients who have received other standard of care molecular tests (for example, next-generation sequencing) and if so, provide useful information for current and future cancer patients.

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A Department of Inova Fairfax Hospital

• Diagnosis of pathologically confirmed cancer by tumor biopsy and/or fine-needle aspiration
• Patient must have sufficient tissue available for the primary analysis intended. Currently for tumor tissue standard DNA analysis this approximates a 10 micron thick section of a diagnostic formalin-fixed block where there is an 8 mm square area of tumor that contains at least 60% tumor cells. For other planned diagnostics such as: RNA sequencing, phosphoprotein analyses, or proteomics the tissue available in archive form or a lesion intended for biopsy must be reasonably likely to match the assay requirements.
• ECOG performance status < 2
• Age ≥ 18 years
• Patient with multiple malignancies is eligible
• The patient must be able to provide written informed consent
• Additional eligibility in protocol

• Patients who have already had tumor NGS testing performed (except if performed already in the context of the Inova Schar Cancer Institute MTB) and who have not experienced disease progression on therapy may not participate (enrollment on this protocol would entail redundant, low value testing)
• Recent hospitalization for co-morbid conditions or any complication of disease or therapy that is deemed by the principal investigator or study designate as unstable or incompletely treated
• A psychiatric or social condition that, in the opinion of the principal investigator, leads them to be unlikely to adhere to the study schedule, proceed to any study related endpoints, or to be unable to evaluate the risk/benefit ration of the study on their own (patients who cannot provide independent informed consent)
• Additional ineligibility in protocol